€370.00
-9.50 (-2.50%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where OR.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
16 interventional · 6 observational
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage .NCT07661004Improvement of anti-aging parametersNon-randomized · Single-masked · Treatment | Not applicable | Not yet recruiting | Device: MASK LED · Combination product: LED MASK AND COSMETIC FORMULA | Photodamage of the Face, Anti Aging | 130 | 2027-04-01 | in 225 d | 2026-06-22 |
| Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 MonthsNCT07556016total hair density on global populationRandomized · Open-label · Supportive care | Not applicable | Active, not recruiting | Dietary supplement: Active nutricosmetic, Placebo Nutricosmetic | Hair Loss | 239 | 2026-07-31 | — | 2026-04-29 |
| Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier RepairNCT07645339Clinical Scoring (Erythema, Dryness, Desquamation, Roughness, Edema, PIH)Randomized · Quadruple-masked · Treatment | Not applicable | Active, not recruiting | Other: Cosmetic Topical Product A, Cosmetic Topical Product B, Vehicle | Impaired Barrier | 35 | 2025-11-03actual | — | 2026-06-16 |
| Antidandruff Lotion Mediating Microbiome RebalanceNCT06813521Global score of dandruff status of the scalp: evaluation of adherent and non-adherent dandruff accordingRandomized · Triple-masked · Treatment | Not applicable | Recruiting | Other: NaP1%+VitCG3% leave-on lotion (formula 1256103), vehicle (formula 1256145), reference Octopirox 0.25% (formula 1256149). | Dandruff | 120 | 2025-05-02 | — | 2025-02-07 |
| My Skin & Hair Journey_virtual RegistryNCT06066463observationalCollect and organize a longitudinal skin & hair beauty registry | — | Suspendedsponsor's stated reason: recruitment issue | Behavioral: questionnaires | Skin, Hair | 10,000 | 2024-10-30actual | — | 2025-11-03 |
| Evaluating Facial Skin Quality Changes Post-LipofillingNCT07737639observationalChange in Wrinkles and Fine Lines Severity | — | Completed | — | Facial Aging | 15 | 2023-11-10actual | — | 2026-07-30 |
| Targeting Staphylococci in Atopic DermatitisNCT05502185observationalIdentification of S. epidermidis adhesins | — | Unknown status | — | Atopic Dermatitis | 60 | 2023-09-01 | — | 2022-08-16 |
| MELASYL EFFICACY UNDER PART OF VISIBLE LIGHTNCT06937515observationalSkin color measurement | — | Completed | Other: Cosmetic topical products | Visible Light Exposure on Healthy Back Skin | 31 | 2023-09-01actual | — | 2025-04-22 |
| Agents Effect Under Visible Light on Caucasian, Asian and Darker Skin TypesNCT07462845observationalSkin color measurement with ITA° angle | — | Completed | — | Visible Light Exposure on Healthy Back Skin | 66 | 2022-12-15actual | — | 2026-03-10 |
| Effects on the Scalp Lipids and TEWL of a 1% Selenium Disulfide and 1% Salicylic Acid Antidandruff Shampoo on Dandruff ScalpNCT05503706Evaluate the change of squame quantity during the antidandruff treatmentDouble-masked · Treatment | Not applicable | Unknown status | Other: 1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo | Dandruff | 40 | Nov 2022 | — | 2022-08-17 |
| Evaluation of the Efficacy of SeS2 Shampoo on Subjects Having DandruffNCT05506592Analysis of microflora from swabs for fungi quantificationRandomized · Quadruple-masked · Treatment | Not applicable | Unknown status | Other: dermatological product | Dandruff | 60 | Nov 2022 | — | 2022-08-18 |
| ANTIPIGMENTING OR DEPIMENTING EFFICACY UNDER PART OF VISIBLE LIGHTNCT06945393observationalSkin color measurement | — | Completed | Other: Cosmetic topical products | Visible Light Exposure on Healthy Back Skin | 30 | 2022-05-21actual | — | 2025-04-25 |
| Photoprotection Efficacy With Sunscreen Formulas Containing the Cyclic Merocyanine Long-UVA Absorber MCE Under UV Day Light ExposureNCT04866797Biophysical non-invasive assessment of skin color by using ChromameterRandomized · Quadruple-masked · Treatment | Not applicable | Unknown status | Other: cyclic merocyanine, Placebo | Pigmentation, Redness | 50 | 2021-06-29 | — | 2021-04-30 |
| Photoprotection Efficacy With Sunscreen Formulas Containing the Cyclic Merocyanine Long-UVA Absorber MCE Under Long-UVA Exposure.NCT04865120Biophysical of skin colorRandomized · Quadruple-masked · Treatment | Not applicable | Unknown status | Other: cream cyclic merocyanine, placebo | Sunscreen Sensitivity, Ultraviolet-Induced Change in Normal Skin | 50 | 2021-06-10 | — | 2021-04-29 |
| Photoprotection Efficacy With Sunscreen Formulas Containing the Cyclic Merocyanine Long-UVA Absorber MCE, Under Real Sun ExposureNCT04865055To compare the photo-protective efficacy of two cosmetic investigational products by Clinical scoring done by the study investigatorRandomized · Quadruple-masked · Treatment | Not applicable | Unknown status | Other: cyclic merocyanine, placebo | Real Life Pigmentation | 50 | 2021-04-29 | — | 2021-04-29 |
| Photoprotection Efficacy With Sunscreen Formulas Containing the Cyclic Merocyanine Long-UVA Absorber MCE Under Long-UVA ExposureNCT04865094Biophysical non-invasive assessment of skin color by using Chromameter Post-UVA pigmentation, ErythemaRandomized · Quadruple-masked · Treatment | Not applicable | Unknown status | Other: cyclic merocyanine, placebo | Pigmentation, Redness | 50 | 2021-04-29 | — | 2021-04-29 |
| Effects on the Scalp Microbiota of a 1% Selenium Disulfide and 1% Salicylic Acid Shampoo After 2% Ketaconazole Foaming Gel Treatment for Scalp Seborrheic DermatitisNCT04057950Antisquame efficacy of the tested shampoo versus its vehicle with Visual Analog Scale after 8 weeksRandomized · Quadruple-masked · Basic science | Not applicable | Completed | Other: cosmetic product | Scalp Dermatitis, Dermatitis | 80 | 2019-09-01actual | — | 2021-04-27 |
| Skin Safety Profile of Different Exposure to the Light Emitting Diode (LED) in Healthy SubjectsNCT00818311Assess the skin toleranceRandomized · Open-label · Basic science | Not applicable | Completed | Device: LED GentleWaves® | Radiation Tolerance, Skin Aging, Rhytids | 100 | Jul 2008actual | — | 2009-01-07 |
| Transcriptomic Study of ER 4017 Topical Application in Elderly SubjectNCT00818545Investigate the effectiveness of an anti aging topical treatment by characterizing molecular modifications linked to barrier function recovery following a disruption of stratum corneum.Randomized · Quadruple-masked · Basic science | Not applicable | Completed | Drug: ER4017 (hydroxypropyltetrahydropyrantriol), placebo | Aging | 10 | Mar 2008actual | — | 2009-01-07 |
| Two Supplemented Against Skin ReactivityNCT01368224skin sensitivity and skin barrier reconstructionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Dietary supplement: Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001 | Skin Sensitivity, Trans-epidermal Water Loss, Clinical Score, Assessment of Skin Moisturization Factors, Assessment of Serum Immune-regulatory Cytokine, Evaluation of Intestinal Flora Composition | 96 | Mar 2006actual | — | 2011-06-07 |
| Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV RadiationNCT00351689Evaluation of food supplement effect on the functions of epidermal cells after UV radiation exposure.Randomized · Double-masked · Treatment | Phase 1 | Completed | Behavioral: dietary supplement | Photobiology | 50 | — | — | 2012-10-03 |
| Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic ProbandsNCT00509535Clinical evaluation SCORAD. In addition a visual analogue scale for subjective estimation of pruritusRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: vitreoscilla filiformis cream | Atopic Dermatitis | 75 | — | — | 2007-07-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19